Obesity & OverweightProject ZestNCT07789106
A Study on Ubiquinol on Fatigue and Muscle Strength in Healthy Adults Taking GLP-1 Agonists
A study testing Ubiquinol 100 MG Oral Capsule in people with Obesity & Overweight and GLP - 1, run by StudySetGo at 1 site in United Kingdom.
Trial summary
The goal of this clinical trial is to learn if a daily ubiquinol supplement can reduce fatigue and help maintain muscle strength in adults aged 30-65 who are taking a GLP-1 weight loss medication (Wegovy® or Mounjaro®). Read more about this study
- Who is it for?
- Ages 30 to 65 years
- Conditions the study is for
- Obesity & Overweight, GLP - 1, Fatigue Severity Scale
- What is being tested?
- Ubiquinol 100 MG Oral Capsule
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 90 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 1 Sep 2026to 1 Sep 2028
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 30-65 years
- Body mass index >27kg/m2 and <35 kg/m2
- Currently initiating, or has initiated within the preceding 16 weeks of screening, one of the following MHRA-licensed weight management pharmacotherapies: semaglutide 2.4mg (Wegovy®) or tirzepatide (Mounjaro®) prescribed for the indication of weight management.
- Is physically mobile and able to complete at least one sit to stand movements
- Owns a smartphone (iOS 15.6 or later, Android 9 or later) and is willing and able to install the SANNO Health app
- Proficient in English language speaking and reading
- Owns their own digital body weighing scale
- Able and willing to provide full informed consent
Who cannot join
- Prior use of ubiquinol or Co-enzyme Q10 within 3 months of screening
- Diagnosed condition which, in the opinion of the Chief investigator, may independently impact fatigue (e.g. type 1 or type 2 diabetes, cardiovascular disease, obstructive sleep apnoea, inflammatory or autoimmune conditions, cirrhotic or advanced liver disease, malignancy)
- Prior or current use of statin medication
- Has previously used GLP-1 agonists and/or undergone bariatric surgery
- Other medications, which in the opinion of the Chief Investigator, may deplete CoQ10
- Failed screening bloods (any results that is outside of the lab reference range)
- Intention to stop GLP-1 agonist use within 9 months of randomisation
- Pregnancy, breastfeeding or intention to conceive during study
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom1 site, 1 recruiting
- Recruiting
Office 1110 3 Fitzroy Place, 1/1, Sauchiehall Street
Glasgow, G3 7RH
Tom Jameson, tom.jameson@studysetgo.com
Tom Jameson, PhD, 7794865520 ext. 44, tom.jameson@studysetgo.com
About this study
Official title: A Randomised, Placebo-Controlled Trial to Evaluate the Effect of Ubiquinol on Fatigue and Muscle Strength in Healthy Adults Who Are Self-Administering GLP-1 Agonists ("Project Zest")
The goal of this clinical trial is to learn if a daily ubiquinol supplement can reduce fatigue and help maintain muscle strength in adults aged 30-65 who are taking a GLP-1 weight loss medication (Wegovy® or Mounjaro®). Ubiquinol is a form of Coenzyme Q10 (CoQ10), a substance the body makes naturally that plays a key role in energy production. The main questions it aims to answer are:
Does ubiquinol lower fatigue levels compared to a placebo (a look-alike capsule that contains no ubiquinol)? Does ubiquinol help maintain muscle strength during weight loss treatment?
Read more
Researchers will compare ubiquinol to a placebo to see if ubiquinol helps with fatigue and muscle strength in people using GLP-1 medications.
Participants will:
Take one ubiquinol (100 mg) or placebo capsule every day for 9 months Have a nurse visit their home 4 times (at months 0, 3, 6, and 9) to take a small blood sample, measure their body, and supervise a simple sit-to-stand exercise test. Attend a short monthly video call (about 20-30 minutes) with a study dietitian. Complete questionnaires and 4 days of diet logging every 3 months using a smartphone app. Log all exercise sessions in the smartphone app throughout the study.
This is a fully remote study - participants do not need to visit a clinic. About 90 people will take part.
- Being tested
- Ubiquinol 100 MG Oral Capsule, Placebo
- Medical subject headings
- Obesity, Overweight
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ubiquinol 100 MG Oral CapsuleDietary supplement
The active intervention is a commercially available ubiquinol dietary supplement. The dose is one 100mg capsule per day taken.
PlaceboDietary supplement
The placebo is manufactured by the same manufacturer that produces the active product. The placebo is visually similar to the active product and will be packaged in the same bottles as the active intervention to maintain the blind. The dose is one 100mg capsule per day taken with the first meal of the day. The product is stored at room temperature.
| Study group | Role | What they receive |
|---|---|---|
| Ubiquinol | Experimental | Not described Receives: Dietary Supplement: Ubiquinol 100 MG Oral Capsule |
| Placebo | Placebo comparator | Not described Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Self-reported fatigue
Measured via Chalder Fatigue Scale score
Measured: 9 months
Secondary outcomes (18)
Quality of life questionnaire
Measured via WHOQoL-BREF
Measured: 9 months
Skeletal muscle function
Measured via 5 x sit-to-stand test
Measured: 9 months
Body Mass
Body Mass measured in kg
Measured: 9 months
Blood pyruvate levels
At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by a third party company, following their own standard operating procedures.
Measured: 9 months
Blood Lactate levels
At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by a third party company, following their own standard operating procedures.
Measured: 9 months
Blood Coenzyme Q10 levels
At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by a third party company, following their own standard operating procedures.
Measured: 9 months
Blood Creatine Kinase levels
At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by a third party company, following their own standard operating procedures.
Measured: 9 months
Blood Vitamin D levels
At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by a third party company, following their own standard operating procedures.
Measured: 9 months
Blood Ferritin levels
At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by a third party company, following their own standard operating procedures.
Measured: 9 months
Blood Magnesium levels
At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by a third party company, following their own standard operating procedures.
Measured: 9 months
Blood Total Cholesterol levels
At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by a third party company, following their own standard operating procedures.
Measured: 9 months
Blood LDL levels
At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by a third party company, following their own standard operating procedures.
Measured: 9 months
Blood HDL levels
At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by a third party company, following their own standard operating procedures.
Measured: 9 months
Blood Triglycerides levels
At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by a third party company, following their own standard operating procedures.
Measured: 9 months
Blood Vitamin B12 levels
At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by a third party company, following their own standard operating procedures.
Measured: 9 months
Blood HBA1C levels
At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by a third party company, following their own standard operating procedures.
Measured: 9 months
Height
Measured in metres
Measured: 9 months
Body Mass Index
Measured in kg/m²
Measured: 9 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Aug 2026
- Study start1 Sep 2026
- Primary completion1 Dec 2027 (estimated)
- Study completion1 Sep 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Obesity & OverweightStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 90 participants (estimated)
Sponsor and investigators
- Lead sponsor
- StudySetGo
- Sponsor type
- Research network
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07789106
- Sponsor's protocol ID
- SSG-26-002-001
- Acronym
- Project Zest
- Status last verified
- Oct 2026
- First submitted
- 11 Aug 2026
- Last updated
- 19 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided